AbCellera Biologics
ABCL
142 hedge funds and large institutions have $680M invested in AbCellera Biologics in 2023 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 20 closing their positions.
168% more call options, than puts
Call options by funds: $7.64M | Put options by funds: $2.85M
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
23% more capital invested
Capital invested by funds: $552M → $680M (+$128M)
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
3% more funds holding
Funds holding: 138 → 142 (+4)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.46% less ownership
Funds ownership: 41.48% → 41.02% (-0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$9.95M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$8.69M |
| 3 |
BlackRock
New York
|
+$2.3M |
| 4 |
Goldman Sachs
New York
|
+$1.58M |
| 5 |
Two Sigma Advisers
New York
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$10M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$3.88M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$3.46M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.31M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.88M |
ABCL Hedge Fund Activity: Q4 2023 in Review
142 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2023, worth a combined $680M — up 23% from $552M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ABCL positions and 20 closed out — a net gain of 6 holders — while 45 added to existing stakes and 37 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $9.95M. The largest seller was Baillie Gifford & Co, cutting an estimated $10M.
- 142 institutional investors held AbCellera Biologics (ABCL) as of Q4 2023, up from 138 in Q3 2023.
- Funds reported $680M of AbCellera Biologics stock for Q4 2023, up 23% quarter-over-quarter.
- 26 funds opened new AbCellera Biologics positions in Q4 2023 and 20 closed out, a net change of +6 holders.
- The largest AbCellera Biologics buyer in Q4 2023 was Baker Bros. Advisors, an estimated $9.95M added.
- The largest AbCellera Biologics seller in Q4 2023 was Baillie Gifford & Co, an estimated $10M sold.
Based on aggregated 13F filings for Q4 2023.